Drug Profile


Alternative Names: APZ1; APZ2

Latest Information Update: 15 Apr 2016

Price : $50

At a glance

  • Originator RHEACELL
  • Class Stem cell therapies
  • Mechanism of Action ATP-binding cassette transporter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Varicose ulcer

Most Recent Events

  • 29 Mar 2016 Phase-I/II clinical trials in Varicose ulcer (In adults, In the elderly) in Germany (Topical) (EudraCT2015-000399-81)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top